london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Intravitreal anti-vascular endothelial growth factor injections for idiopathic choroidal neovascularization- long-term visual outcome

Poster Details

First Author: M.Onen TURKEY

Co Author(s):    Z. Yazar   N.I. Ucgun   H. Sarikatipoglu            0   0 0   0 0   0 0   0 0

Abstract Details


To evaluate the long-term visual outcome after intravitreal anti-vascular endothelial growth factor (VEGF) injections for idiopathic choroidal neovascularization (CNV)


DESIGN: Retrospective observational study.



The medical records of 6 eyes (6 patients) with subfoveal or juxtafoveal idiopathic CNV who were treated with anti-VEGF injections were analyzed. All patients completed at least 2 years of follow-up. Bevacizumab (5 eyes) and ranibuzimab (1 eye) were used as anti-VEGF. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMAR]), imaging data of fluorescein angiography, and optical coherence tomography, were investigated.



Mean age was 28.6 ± 9.1 years. During a mean follow-up period of 37.8 ± 8.8 months, a mean of 3.5 ± 1.0 intravitreal anti-VEGF injections were performed. During follow-up, 1 eye (16.6%) showed recurrence. Mean BCVA was 1.06 ± 0.45 logMAR (20/226 Snellen equivalent) at baseline and 0,24 ± 0,14 logMAR (20/34 Snellen equivalent) at 2 years. At 2 years, 4 patients (66.6%) gained 0.3 logMAR or more BCVA than baseline.



Intravitreal anti-VEGF injections showed favorable visual outcomes, and significant visual improvement was maintained in idiopathic CNV patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy